Abstract Library

#1930 Concomitant Intraductal Papillary Mucinous Neoplasms and Neuroendocrine Tumors of the Pancreas: More than just a Coincidence?

Introduction: Intraductal papillary mucinous neoplasms (IPMNs) and pancreatic neuroendocrine tumors (pNETs) are rare tumors. Up to now 14 patients with association of endocrine and exocrine neoplasms of the pancreas have been reported in literature: this association is not expected to be frequent

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Cortegoso Valdivia P

Authors: Venezia L, Cortegoso Valdivia P, De Angelis C,

Keywords: IPMN, NET, pancreas,

#1430 Cystic Neuroendocrine Tumors of the Pancreas (c-pNETs): A Single-Center Experience.

Introduction: c-pNETs are rare and may be less aggressive than their solid counterparts

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Coakley M, Kommineni V, Pannala R, Chen L, Zhang J,

Keywords: Pancreatic NETs, cystic, prognosis,

#1092 Experience of Two European Centers on Central Pancreatectomy for NeuroEndocrine Tumors of the Pancreas

Introduction: Central pancreatectomy (CP) is a parenchima-sparing operation that enables the removal of benign or low-grade malignant lesions from the neck of the pancreas.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Milanetto A

Authors: Milanetto A, Pasquali C, Lico V, Büchler M, Hackert T,

Keywords: net, central pancreatectomy,

#990 Prolonged Progression-Free Survival with Extended Cycle Streptozotozin/5-FU Chemotherapy in Patients with Metastatic Pancreatic Neuroendocrine Tumors

Introduction: The treatment of pancreatic neuroendocrine tumors with streptozotocin-based chemotherapy is well-established.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Schrader J, Zimmermann-Fraedrich K, Benten D, Pace A, Bläker M,

Keywords: chemotherapy,

#827 Neuroendocrine Tumors of the Pancreas Grade 2 with Ki-67 Index More Than 5% and with Expression Cytokeratin 19 are the Risk Group of Rapid Progression

Introduction: Cytokeratin 19 (CK19) is the marker of pluripotent cells of the epithelium of the pancreatic ducts, which is not detected in differentiated endocrine cells. Our experience shows that many patients with neuroendocrine tumors of the pancreas (pNET) G2 have a rapid progression of the disease a few years after diagnosis, and metastases are found most commonly in the liver.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Gurevich L, Korsakova N, Kazantseva I, Egorov A, Britvin T,

Keywords: pancreas, neuroendocrine tumors, risk factors, Ki-67, cytokeratin 19,